Stockreport

Keros Therapeutics to Present at Leerink Partners 2024 Global Biopharma Conference

Keros Therapeutics, Inc. - common stock  (KROS) 
PDF LEXINGTON, Mass., March 05, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developin [Read more]